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TropismTherapeutic gene transfer by adeno-associated virus of serotype 2 (AAV-2) vectors is hampered in patients
with pre-existing immunity. Molecular engineering was recently used to identify key immunogenic amino
acid residues of the viral capsid and generate mutants with decreased antibody recognition. Here we
explored the importance of ﬁnely tuning amino acid identity at immunogenic sites to optimize vector
phenotype. A capsid library was generated by codon randomization at ﬁve positions where substitutions
were shown to yield antibody evading phenotypes. Screening this library to isolate immune-escaping
mutants allowed an exhaustive scan of combinations of the 20 natural amino acids at each position and
yielded variants that remained infectious when incubated with serum or IVIG concentrations that completely
neutralize AAV-2. Clones obtained replacing different residues at the same positions displayed strikingly
different phenotypes, demonstrating that a precise choice of amino acid substitutions is fundamental to
optimize immune-escaping, packaging ability, infectivity and tropism.
© 2009 Elsevier Inc. All rights reserved.Introduction
Adeno-associated viruses have become popular vectors for
therapeutic gene transfer and clinical trials are being performed
employing different AAV serotypes (Mueller and Flotte, 2008). Since
no known pathology has been associated to AAV infection, and
because the viral capsid elicits only mild immune responses, these
vectors offer a robust safety proﬁle (Buning et al., 2008). Furthermore,
AAV vectors can be produced at high titers and transduce a number of
different tissue types due to their wide tropism (Wu et al., 2006).
However, viruses belonging to this genre are widespread in nature
and the majority of the human population possess antibodies that
would neutralize or reduce vector transduction rates (Chirmule et al.,
1999; Fisher et al., 1997; Moskalenko et al., 2000; Xiao et al., 2000).
Moreover, even naive patients will generate anti-AAV antibodies
upon vector application, hindering a second successful vector
application when required. Use of vectors derived from alternative
serotypes that do not cross-react with neutralizing antibodies can
circumvent this problem in some cases (Boissier et al., 2007; Calcedo
et al., 2009; Wu et al., 2006), but differences in viral tropism betweene, Clinic I for Internal Medicine,
y. Fax: +49 221 4786383.
).
ll rights reserved.natural capsid variants restrict the viability of this solution. Therefore,
different techniques have been recently employed to generate
“stealth” viral mutants that escape recognition by human antibodies.
In these studies, structural modiﬁcations are genetically introduced in
the capsid, resulting in disruption of immunogenic epitopes and in
reduced antibody binding afﬁnity. Mutations introduced to redirect
AAV-2 tropism for example, have been shown to decrease binding and
neutralization by pre-existing antibodies (Huttner et al., 2003). This
principle has been eventually exploited to generate ad hoc immune-
escaping viral mutants by amino acid substitutions at the viral capsid
surface by rational design or by directed evolution approaches
(Huttner et al., 2003; Lochrie et al., 2006; Maheshri et al., 2006;
Perabo et al., 2006a). These works identiﬁed several amino acid
residues whose substitution decreased binding of human or rabbit
antibodies and improved transduction efﬁciencies after incubation
with diluted sera or IVIG. However, even if combinatorial libraries
allow screening larger numbers of mutations than rational design
approaches, scanning of amino acid substitutions on the capsid
surface is not exhaustive when randomization of large capsid protein
fragments is required. In the study of Perabo and colleagues for
example, a fragment of 414 amino acidswas randomized resulting in a
pool of clones carrying 5 mutations per clone (Perabo et al., 2006a).
Since the number of possible clones carrying n amino acid substitu-
tions over a fragment of L residues is [L!/(L-n)!]×1/n!×20n, a
Fig. 1. (A) Location of the ﬁve randomized positions (red). Protruding residues at the three- and ﬁve-fold symmetry regions (indicated by numbers) are depicted in white to facilitate
topology visualization. (B) Library panning procedure.
168 S. Maersch et al. / Virology 397 (2010) 167–175library containing 3.2×1017 different clones would have been
required to represent all possible amino acid combinations, while
9.9×1010 clones would be required to represent one single amino
acid substitution at each site. Since technical limitations currently
restrict biodiversity of capsid libraries to a maximum of approxi-
mately 107–108 different clones, only a minimal fraction of the
possible amino acid combinations at each position is represented.
Therefore, despite being a powerful method to identify relevant
immunogenic epitopes, error prone PCR randomization and selection
protocols are likely to identify amino acid substitutions that are
suboptimal in terms of stealth phenotype, transduction efﬁciency,
stability or other important characteristics of the vector.
To prove the importance of optimizing amino acid composition of
immune-escaping mutants, here we combined rational design and
evolutionary approaches randomizing ﬁve previously identiﬁed
immunogenic residues located at positions 449 and 458 (our own
unpublished results), 459 and 551 (Perabo et al., 2006a) and 493
(Maheshri et al., 2006) of the structural proteins ORF (cap) of AAV-2
(Fig. 1A). We obtained a library of approximately 6×106 different
clones which is likely to represent the majority of the possible
combinations of 20 amino acids at these ﬁve positions (205). The
library was panned to isolate mutants that efﬁciently infect target
cells in the presence of high concentrations of neutralizing antibodies.
Selected clones were characterized with respect to immune-escaping
phenotype, packaging ability and tropism.
Results
Selection of immune-escaping mutants
A capsid library containing approximately 6×106 different clones
was produced by randomization of ﬁve codons corresponding to
positions 449, 458, 459, 493 and 551 (VP1 numbering) of the
structural proteins of AAV-2. The pool was panned performing four
selection rounds as depicted in Fig. 1B. Brieﬂy, HEK293 cells were
infected with the capsid library in the presence of an AAV-2neutralizing human serum (S1) and viral progeny collected from
cell lysates 48 h after infection. Forty-one clones of the original library,
and 43 clones of the pool collected after four selection rounds were
sequenced (Fig. 2).
Even if no predominant clone was observed (only a single mutant
was recovered twice), compared to the initial library the diversity of
different amino acids at each position decreased substantially as result
of the selective pressure applied during the screening procedure
(Table 1). The relative amount of small hydrophilic amino acids
increased, while the fraction of large, hydrophobic amino acids
decreased at all ﬁve positions. This presumably reﬂects the greater
likeliness of small, hydrophilic amino acids to be tolerated by the
capsid architecture, a tendency also suggested by previous experi-
ments (Perabo et al., 2006b). In addition, the increase of small and
hydrophilic amino acids at position 493 is in agreement with previous
experiments showing that a A493G substitution halved neutralization
of the viral capsid by rabbit anti-AAV-2 serum (Maheshri et al., 2006).
The abundance of alkaline amino acids decreased at all positions,
however was well tolerated at position 459 (-20%), in accordance to
previous selection experiments that identiﬁed stealth mutants with a
R459K substitution (Perabo et al., 2006a). Interestingly, while acidic
amino acids completely disappeared from positions 449, 458, 459 and
493 after selection, their frequency doubled at position 551. This is in
accordance with previous results showing that substitution of the
original asparagine with aspartate at position 551 resulted in an
immune-escaping phenotype (Perabo et al., 2006a).
Packaging ability of selected mutants
Four clones of the original library, four clones collected after two
selection rounds, and eight clones collected after four rounds were
chosen randomly, packaged as GFP-expressing vectors and charac-
terized with regard to their packaging capacity (Table 2). These
mutants were compared to AAV-2, AAV-1 (a natural serotype with
120 amino acid differences on the capsid protein that does not cross-
react with anti-AAV-2 antibodies (Sun et al., 2003; Xiao et al., 1999)),
Fig. 2. Sequences of the viral library before selection (A) and after the fourth selection round (B). The sequence of wt-AAV-2 is indicated on top.
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Table 1
Percentage variation of occurrence of different amino acid types between library
(n=41) and selected pool (n=43) at each randomized position.
Amino acid position 449 458 459 493 551
wt N S R A N
Biodiversity −56% −36% −47% −56% −41%
Small, hydrophilic +118% +20% +55% +94% +6%
Big, aromatic, hydrophobic −71% −43% −32% −15% −40%
Alkaline −100% −58% −20% −100% −71%
Acidic −100% −100% −100% −100% +100%
170 S. Maersch et al. / Virology 397 (2010) 167–175and K4, the best mutant isolated from an error prone PCR library in
our previously published experiments (Perabo et al., 2006a).
Capsid titers (ranging from 1.6×108 to 8.2×109), genomic titers
(ranging from2.2×106 to 5.2×108) and their ratio (between3 and23)
were comparable to AAV-2, suggesting that the selection procedure
eliminates clones with substitutions that interfere with the packaging
process. Accordingly, the eight clones isolated in the fourth selection
round yielded on average higher genomic titers than those selected
after two rounds, which in turn had higher titers than those chosen
among the unselected pool (Table 2). Since capsid titers remained
similar before and after selection, the proportion of full particles
increased during selections. Noteworthy, the mutant that yielded the
lowest titer included two cysteins, a methionine and an aspartate
among substituted residues,which being bulky (Cys andMet) or acidic
(Asp), accordingly to the observations reported in the previous section
are expected to interfere with the ﬁtness of the capsid.
Transduction ability in the presence of neutralizing sera
To test their immune-escaping phenotype, clones A11, B2, B10, C6,
H6 (carrying non-wt amino acids at all ﬁve positions, A11, B2 and B10
were chosen for comparison since they are similar), A2 (carrying a
single wt residue at 458), AAV-1, AAV-2 and the K4 mutant were used
to transduce HeLa cells. Infections were performed in the presence of
increasing concentrations of the human serum used in the selection
procedure (S1), a different AAV-2-neutralizing human serum(S2), or a
highly concentrated intravenous immunoglobulin pool (IVIG) derived
from more than thousand healthy individuals and representing an
immunologic average of the human population. Infections were
conducted using identical amounts of genomic particles, total capsidsTable 2
Amino acid substitution, genomic and capsid packaging titers of the selected clones and ra
Vector AA at position 449, 458,
459, 493, and 551
Genomic titer
(/μl)
Mean genomic titer
(/μl)
AAV-2 NSRAN (1.90±0.05)×108
AAV-1 – (2.91±0.17)×107
K4 NSKAD (2.05±0.06)×107
B6 AGSLG (1.43±0.06)×107 2.08×107
B8 TARSA (1.14±0.10)×107
C4 CQCGK (5.55±0.09)×107
C7 ICMDC (2.24±0.05)×106
A2a ASCMG (4.63±0.21)×107 7.17×107
A11a AYGGD (5.10±0.40)×107
B2a AGGGQ (1.32±0.08)×108
B10a AGTTG (5.74±0.19)×107
C6b QQVSA (4.50±0.35)×108 3.05×108
E3b TPQSD (1.15±0.12)×107
E4b AYGTE (5.17±0.58)×108
E10b THCGE (1.91±0.12)×107
F8b GNGTA (3.59±0.16)×108
H6b SGKSG (1.56±0.06)×108
H8b TPQTK (4.73±0.18)×108
H11b SASPG (4.54±0.19)×108
a Recovered after 2nd selection round.
b Recovered after 4th selection round. Bold letters indicate clones selected for detailed imand iodixanol concentrations to make sure that differences between
viral preparations did not inﬂuence the outcome of the experiments.
Transduction rates were quantiﬁed by ﬂow cytometry 48 h post
infection (Fig. 3). The amount of serum needed to halve transduction
rates (N50)was extrapolated from this data set in order to quantify the
immune-escaping ability of themutants (Table 3). Relative N50 values
(rN50) were calculated dividing the N50 value of the mutants by the
N50 value of AAV-2 to quantify the beneﬁcial effect of the mutations
with regard to immune-escaping. Relative infectivity values were
calculated dividing the number of cells transduced by the mutants in
the absence of serum, by the number of cells transduced by AAV-2.
Depending on the type of substitutions at the same ﬁve sites,
relative N50 of analyzed clones ranged from 0.5 to 5.1 while relative
infectivity ranged from 0.39 to 1.14, demonstrating the importance of
the exact nature of amino acid exchange. Also noteworthy in this
regard are the remarkable differences in N50 and infectivity values
observed between mutants A11, B2 and B10 despite their similarity.
N50 values obtained for IVIG were lower than those obtained for S1
and S2. This is likely to depend on the higher concentration of
immunoglobulins in IVIG (50 mg/ml) than in human serum
(approximately 5–18 mg/ml). AAV-1 showed the highest relative
N50 values on all sera, but when tested on the serum used in the
selection procedure (S1), the values of the selected mutants were
closer to those obtained for AAV-1, suggesting that the screening
procedure identiﬁes mutations that are optimized for the speciﬁc
serum used for the selection. Accordingly, even if immune-escaping
phenotypes were similar on S1, S2 and IVIG for B10, C6, A11, H6 (rN50
values N1) and A2 (rN50 values b1), serum-speciﬁc oscillations can be
observed and remarkably, B2 yielded rN50 values N1 on S2 and b1 on
IVIG (rN50 of B2 was not determined on S1 due to serum exhaustion).
The comparison of N50 and infectivity values with the neutrali-
zation proﬁles of each mutant underlines that the ability to escape
antibody neutralization results from a combination of two factors: the
ability to elude antibody binding and the efﬁciency of cell trans-
duction. For example, while the N50 of B10 on S2 is 1.05-fold better
than H6, due to its higher infectivity H6 infects a higher amount of
cells in the presence of neutralizing antibodies. Conversely, despite
being generally less infectious, AAV-1 infects more cells than H6 at
high concentrations of S2 thanks to higher N50 values (Fig. 3). In all
other settings, combining good N50 values and superior infectivity,
H6 yielded the highest transduction rates in the absence or presence
of all tested sera.tio of empty to full capsids of packaged GFP-vectors.
Capsid titer
(/μl)
Mean capsid titer
(/μl)
Capsids/Genome Mean capsids/
Genome
1.18×109 6.2
n.d. n.d.
4.61×108 23
n.d. 1.31×108 n.d. 16.5
1.60×108 14
1.03×109 19
n.d. n.d.
9.44×108 2.59×108 20 11.975
8.18×109 16
1.01×109 8
2.29×108 3.9
1.74×109 1.45×108 4 8.625
2.38×108 21
2.90×109 6
3.06×108 16
1.86×109 5
1.57×109 10
1.38×109 3
1.59×109 4
mune-escaping characterization.
Fig. 3. Neutralization assay. Prior to infectionGFP-vectorswere incubatedwith increasing amounts of S1 (upper panels), S2 (center panels) or IVIG (lowerpanels). In left panels, AAV-2 (black) is
shown togetherwithAAV-1 (green), K4mutant (blue), A11mutant (orange) andH6mutant (red). On the right, AAV-2 is shownwithA2 (dark yellow), B2 (olive), B10 (cyan) andC6 (dark red).
Measurementswith S1were performed as single experiment because the serum stockwas exhausted after the selection rounds. The curve of A2with S1 could not be calculated correctly since
two data points were missing.
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Table 3
N50 values, rN50 values and r infectivity (compared to AAV-2) of the tested vectors on
S1, S2 and IVIG.
AAV-2 AAV-1 K4 A2 B2 B10 A11 C6 H6
N50 (S1) 2.89 14.51 2.70 1.72 n.d. 6.08 4.02 5.81 7.45
rN50 (S1) 1 5.0 0.9 0.6 n.d. 2.1 1.4 2.0 2.6
r infectivity (S1) 1 0.26 1.14 0.62 n.d. 0.86 0.79 1.08 1.14
N50 (S2) 2.16 37.78 3.61 1.02 5.02 6.06 8.48 3.29 5.79
rN50 (S2) 1 17.5 1.7 0.5 2.3 2.8 3.9 1.5 2.7
r infectivity (S2) 1 0.30 1.07 0.67 0.39 0.82 0.89 0.96 1.10
N50 (IVIG) 0.21 4.05 0.24 0.20 0.05 0.70 0.45 0.33 1.08
rN50 (IVIG) 1 19.3 1.1 0.1 0.2 3.3 2.1 1.6 5.1
r infectivity (IVIG) 1 0.25 1.08 0.73 0.43 0.71 0.72 0.89 1.13
B2 could not be tested on S1 due to serum exhaustion.
Fig. 4. Decoy assay for AAV-2, A11 and H6 mutant. Same amounts of AAV-2 vectors
were mixed with 5-, 10- and 20-fold empty particles of AAV-2 (top), H6 (middle) or
A11 (bottom). After incubation with serial dilutions of S2, HeLa cells were infected and
transduction rates measured 48 h later.
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Since they showed the best N50 values, two mutants A11 (best on
S2) and H6 (best on S1 and IVIG) were further investigated for their
ability to bind human antibodies independently from their infectivity,
packaging efﬁciency and efﬁciency of transgene expression. To
quantify their binding to anti-AAV-2 antibodies, same amounts of
GFP-expressing AAV-2 vectors were mixed with different amounts of
AAV-2, A11 or H6 empty particles and incubated with increasing
amounts of S2. Transduction rates were quantiﬁed by ﬂow cytometry
(Fig. 4). In this setting, empty virions act as decoys for neutralizing
antibodies contained in the serum and diminish the neutralizing
power of the serum proportionally to their afﬁnity for the capsids. N50
values obtained were extrapolated from this data set (Table 4). While
the addition of AAV-2 empty capsids increased N50 values propor-
tionally in a dose-dependent manner (11.51-fold after addition of the
highest empty capsids dose), the increase obtained by addition of
empty H6 capsids was weaker (8.53-fold) and the addition of A11
capsids resulted in no signiﬁcant increase (1.63-fold). These data
demonstrate that while wt efﬁciently binds anti-AAV-2 antibodies, H6
capsids are bound at reduced efﬁciency and A11 capsids escape
recognition and are very inefﬁcient decoys.
Consequences of amino acid substitutions on vector tropism
The transduction ability of mutants A11, H6, AAV-1 and AAV-2
was assessed on a panel of cell lines: human melanoma cells (BLM
and MV3), human breast cancer cells (MDA), human embryonic
kidney cells (293), human keratinocytes (HaCat), and murine
embryonic ﬁbroblasts (NIH3T3) (Fig. 5A). These results were used
to calculate the relative infectivity of the mutants, dividing for each
cell line the transduction rates of a vector by the transduction rate of
AAV-2 (Fig. 5B). Compared to AAV-2, H6 yielded higher transduction
rates in all tested cell types (from 1.15- to 1.71-fold higher).
Conversely, A11 yielded lower relative transduction rates than AAV-2
(0.09- to 0.23-fold lower). AAV-1 yielded lower transduction rates on
most cell lines (between 0.1- and 0.27-fold), but was comparable to
AAV-2 on HEK293 cells (0.89-fold). Therefore, while large structural
differences distinguishing different natural AAV serotypes result in a
radically different tropism, immune-escaping mutants carrying a
limited number of appropriate mutations, depending on the identity
of the introduced amino acids can retain a tropism that resembles (or
even outperforms) the original. This hypothesis was corroborated
infecting HeLa cells in the presence or absence of soluble heparin, an
analog of HSPG, the primary receptor of AAV-2 and measuring
transduction rates 48 h later (Fig. 6). While the ﬁve amino acid
substitutions did not disrupt the ability of the capsid to interact with
the primary receptor of AAV-2, the over 120 amino acid differences
of AAV-1 abolished the ability of AAV-1 to recognize and interact
with HSPG.Discussion
The possibility to modify by genetic engineering the molecular
topology of vector particles and disrupt immunogenic domains has
opened the possibility to tailor a new generation of virions that escape
Table 4
Analysis of decoy efﬁciencies of AAV-2, H6 and A11 empty particles.
Type of empty capsids N50 increase (x-fold)
5× 10× 20×
AAV-2 2.95 5.48 11.51
H6 2.08 2.70 8.53
A11 0.88 1.46 1.63
N50 values after addition of 5×, 10× or 20× empty capsids were extrapolated from Fig. 4
and the x-fold increase in comparison to the N50 obtained without addition of empty
particles was calculated.
Fig. 6. Transduction efﬁciencies of AAV-2, A1, AAV-1 and H6 on HeLa cells in the
presence (black bars) or absence (white bars) of soluble heparin.
173S. Maersch et al. / Virology 397 (2010) 167–175neutralization in seropositive patients. Proof of this principle has been
provided by pioneering studies that identiﬁed several immunogenic
residues on the viral surface and described capsid mutants with
diminished recognition by antibodies (Lochrie et al., 2006; Maheshri
et al., 2006;Moskalenko et al., 2000; Perabo et al., 2006a;Wobus et al.,
2000; Wu et al., 2000). These results suggest the presence of a main
immunogenic region located around the characteristic peaks at the 3-
fold symmetry region of the AAV-2 capsid and have shown that
combination of mutations of several residues in the same clone
increases the immune-escaping phenotype. Directed evolution high
throughput protocols have been recently introduced to take advantage
of the possibility to generate by error prone PCR millions of different
clones, and to screen them by relatively simple procedures. These
studies contributed to the identiﬁcation of important immunogenic
epitopes that can bemutated to decrease antibody recognition, but the
biodiversities of theused libraries allowed representations of aminimal
fraction of possible combinations of different mutations at each site.
Since different amino acids can confer very diverse biochemical
properties to the capsid,we speculated that phenotype of viral particles
could be considerably improved by optimizing the speciﬁc amino acidFig. 5. Absolute (A) and relative (B) infectivities of AAV-2, A11, AAV-1 and H6 on
various cell lines.substituted at each site in order to isolate the best combinations.
Restricting randomization toﬁveaminoacidpositions,whosemutation
was previously shown to inﬂuence binding of neutralizing antibodies,
allowed the generation of a library that represents most possible
combinations of natural amino acids at these positions.
The ﬁrst demonstration of the importance of this approach is the
statistical predominance of particular amino acids at the randomized
positions after selection. Besides providing valuable information of
structural requirements of the virus surface for future capsid
engineering attempts, the preference for amino acid with particular
biochemical characteristics (e.g. acidic residues at position 551, small
and hydrophilic residues at all other positions) demonstrates that a
precise choice of amino acid substitutions is pivotal for the
optimization of engineered capsids. Accordingly, detailed character-
ization and comparison of several mutants isolated after the selection
procedure carrying different substitutions at the same ﬁve positions
highlighted dramatic differences in immune-escaping ability, infec-
tivity and tropism. Although the packaging ability of the viral mutants
is expected to be strongly inﬂuenced by different amino acid
substitutions, all tested clones packaged at high titers, reﬂecting the
fact that inefﬁciently assembling clones are rapidly eliminated from
the viral pool independently of the selection conditions. Conversely,
with regard to infectivity and immune-escaping ability, a wide
spectrum of phenotypes was recovered after selection because during
the selection process, mutants with low infectivity could be rescued
by a strong immune-evading phenotype and vice versa. In addition,
screening procedures are “leaky” and occasional surviving of
inefﬁcient clones occurs. This could explain the isolation after two
selection rounds of mutant A2, which showed poor infectivity and
was neutralized more efﬁciently than AAV-2 by all tested antibodies.
Noteworthy, mutants B10 and H6, showing the best N50 values on S1
and IVIG host at positions 459, 493 and 551 different substitutions
than those most strongly selected in previous experiments (Maheshri
et al., 2006; Perabo et al., 2006a), suggesting the importance of ﬁne
tuning amino acid identity.
AAV natural serotypes can be used as alternatives to circumvent
pre-existing immunity (Boissier et al., 2007; Calcedo et al., 2009; Wu
et al., 2006) because major sequence and structural differences confer
to these variants the ability to escape neutralization by antibodies
directed against another serotype. In this study for example, AAV-1, a
natural occurring variant with different amino acid composition at
120 sites, clearly outperformed all mutants selected in these
experiments in terms of antibody elusion. However, major capsid
modiﬁcations result in dramatic tropism alterations as demonstrated
in experiments depicted in Fig. 5. Conversely, modifying a restricted
number of residues is less likely to affect tropism of the resulting
particle. Infection tests conducted on a panel of cell lines
174 S. Maersch et al. / Virology 397 (2010) 167–175demonstrated that H6 conserved a tropism that is very similar to AAV-
2. Interestingly, even if different mutations of the same ﬁve positions
carried by mutant A11 and H6 did not affect the ability to bind HSPG,
they inﬂuenced infectious rates on HeLa cells (Fig. 5) and yielded
strongly diminished infectivity for mutant A11 (Fig. 6). The 3-fold
symmetry region of AAV-2 capsid has been shown to play an important
role in capsid/receptor interactions. For example, two arginines located
at positions 585 and 588 are responsible for binding HSPG (Kern et al.,
2003; Opie et al., 2003; Xie et al., 2002) and the virus primary receptor
(Summerford and Samulski, 1998). Another domain located at position
511–513has been shown to be responsible for the binding of the capsid
toα5β1 integrins (Asokan et al., 2006). Depending on the nature of the
introduced amino acid, substitutions at the ﬁve positions could
inﬂuence these or other still unknown receptor binding domains and
dramatically alter viral tropism. Although the exact mechanism
responsible for tropism alterations requires further investigation,
tropism differences between AAV-2, H6 and A11 demonstrate once
more the importance of the speciﬁc amino acid substitution.
Despite enhancing antibody evasion, all mutants identiﬁed in this
study were fully neutralized by serum concentrations above 20%
(Fig. 3). The generation of AAV particles with desired tropism that
escape neutralization in vivo remains an ambitious goal that will be
eventually achieved by combining a higher number of different
mutations, resulting in a cumulative effect. Combining separate
substitutions is a complex task because they are usually not compatible
with one anotherwhenmerged on the same clone. However, advances
in understanding capsid biology and the development of powerful
mutagenesis and screening procedures are bringing us closer to this
goal. The diversity of phenotypes obtained by randomizing exhaus-
tively onlyﬁve sites strongly suggests the potential ofﬁne tuning amino
acid identity of substituted residues for optimizing vector character-
istics for therapeutic application. Recently, another powerful solution
has been described to obtain stealth phenotype and tropism modula-
tion by swapping entire antigenic domains between viral serotypes
(Grimm et al., 2008; Koerber et al., 2008; Li et al., 2008). It can be
anticipated that combining rational design, error prone PCR, domain
swapping between serotypes and codon randomization will yield soon
a new generation ofmodiﬁed gene therapy vectors that circumvent the
current limitations.
Materials and methods
Cell culture
The human epitheloid cervix carcinoma cell line HeLa, the human
embryonic kidney cell line 293, the human keratinocyte cell line
HaCat, the human breast cancer cell line MDA and the murine
embryonic ﬁbroblast cell line NIH3T3 were maintained as monolayer
cultures at 37 °C and 5% CO2 in DMEM supplemented with 10% FCS,
100 U/ml penicillin, 100mg/ml streptomycin, and 2mM L-glutamine.
BLM and MV3 melanoma cell lines were maintained in RPMI 1640
supplemented with 10% FCS, 100 U/ml penicillin, 100 mg/ml
streptomycin, and 1% MEM non-essential amino acid solution.
Plasmids and viruses
The complete randomization library plasmid pdegen5Lib was
generated by consecutive PCR steps using following primers to
randomize positions 449, 458, 459, 493 and 551 respectively:
GCAGAACANNSACTCCAAGTGGAACCACCACGCAGNNSNNSCTTCAGTTT,
CGCCATGCTACTTATCTACG, AAACTGAAGSNNSNNCTGCGTGGTGGTTC-
CACTTGGAGTSNNTGTTCTGC, GACATCTNNSGATAACAACAACAGTGAA-
TACTCG , CGAGTATTCACTGTTGTTGTTATCSNNAGATGTC ,
GGCTCAGAGAAAACANNSGTGGACAATG and TCCACSNNTGTTTTCTCT-
GAGCCTTGC. The procedure for the ampliﬁcation of the plasmid library
was described previously (Perabo et al., 2003, 2006a). The biodiversityof the librarywas estimated by counting bacterial colonies after plasmid
ligation and transformation. pXX6, pRC, pscAAV/GFP and the protocol
for the production of AAV were described previously (Perabo et al.,
2003; Xiao et al., 1998). Brieﬂy, HEK293 cells were seeded at 80%
conﬂuence and co-transfected by calcium phosphate (2:3 ratio) of
pdegen5Lib and pXX6 for the production of the AAV-2 library. For the
production of scGFP containing vectors, cells were transfected with a
1:1:3 ratio of pscAAV/GFP, AAV2pRC and pXX6. At 48 h post-
transfection, cells were harvested and resuspended in 150 mM NaCl–
50mM Tris–HCl (pH 8.5), freeze–thawed three times, and treated with
Benzonase for 30min at 37 °C. Cell debriswas spun down at 3700× g for
20 min at 4 °C, and the supernatant loaded onto a discontinuous
iodixanol gradient and centrifuged at 60,000 rpm using a Sorvall T-865
rotor. Genomic titers of vector stocks were determined by quantitative
PCR (Roche, Germany) after purifying viral DNA with the DNeasy kit
(Qiagen,Germany). Selected cloneswere sequenced (Qiagen,Germany)
after puriﬁcation with DNeasy Kit, ampliﬁcation by PCR with Primers
cgccatgctacttatctacg and taccagctcccgtacgtcctcgg and cloning as previ-
ously described (Perabo et al., 2006a). The capsid titers were estimated
by A20 ELISA assay (Grimm et al., 1999). To produce GFP-expressing
vectors of selected mutants, the modiﬁed region of each mutant was
cloned into the pRC plasmid by BsiWI/SnaBI digestion and ligation.
Selection protocol
For selection, the AAV library was incubated for 2h at 37° with
different amounts of human neutralizing serum (33% in the ﬁrst and
second selection round, 50% in the third and fourth). Sera were
obtainedwith informed consent fromhealthy individuals and tested to
assess their ability to neutralize AAV-2 infection (Huttner et al., 2003).
5×106 HeLa cells were infected with a concentration of 100 viral
genomic particles/cell. At the same time, cells were super-infected
with adenovirus type 5 at a concentration of 700 pfu/cell. Cells were
harvested 48 h post infection by scraping and lysed by three cycles of
freeze–thaw. Adenovirus was heat inactivated at 60 °C for 30 min. The
genomic titer of these preparations was measured by qPCR as
described above and eventually used for further selection rounds.
Transduction assays
In 48-well plates, 2×104 HeLa cells were seeded and infected
24 h later with same genomic particles, total capsids and iodixanol
amounts of GFP-expressing AAV vectors after incubation with serial
dilutions of human neutralizing sera or IVIG (Intratect©, Biotest) for
2 h at RT. After 48 h, cells were harvested and GFP expression
measured by ﬂow cytometry (FACSCalibur, BD Biosciences, USA)
analyzing at least 5000 cells. For determination of the decoy
activity of AAV-2 and mutant capsids, 2×104 HeLa cells were
seeded in 48 well plates 24 h before infection. 105, 2×105 or
4×105 of either AAV-2 or mutant empty particles (A11 and H6) were
added to 104 AAV-2 genomic particles per cell. Transduction rates were
measured 48 h later by ﬂow cytometry were performed as described
above. N50 values were calculated by Origin 8 software using the Hill
sigmoidal curve ﬁt: y=START+(END-START)⁎x^n/(k^n+x^n)
(START: max. y-data, END: min. y-data, n=2, k=x at y50).
Heparin competition assay
Twenty-four hour prior to infection 2×104 HeLa cells per well
were seeded in 48 well plates. 6×103 genomic particles of GFP-
expressing viral vectors per cell (6×104 genomic particles per cell for
AAV-1) were incubated in a total volume of 500 μl DMEM/10% FCS in
the presence or absence of 1.7% (85 I.E./ml) soluble heparin (B. Braun
Melsungen AG, Germany) at 37 °C for 30 min. This solution was then
used to infect cells. Forty-eight hours post infection, the percentage of
transduced cells was determined by ﬂow cytometry.
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